PL3670529T3 - Acylowany analog peptydowy oksyntomoduliny - Google Patents

Acylowany analog peptydowy oksyntomoduliny

Info

Publication number: PL3670529T3
Authority: PL; Poland
Prior art keywords: peptide analog; oxyntomodulin peptide; acylated oxyntomodulin; acylated; analog
Prior art date: 2017-08-16

Application number

PL18846196.6T

Other languages

English (en)

Inventor

Jae-Sung Yang

Kyung-Seok Lee

Yu-Na Chae

Gye-Rim BAEK

Tae-Hyoung Kim

Ill-Hun JUNG

Chae-Lim RYU

Weon-Bin Im

Original Assignee

Dong-A St Co., Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-08-16

Filing date

2018-08-16

Publication date

2024-06-10

2018-08-16 Application filed by Dong-A St Co., Ltd. filed Critical Dong-A St Co., Ltd.

2018-08-16 Priority claimed from PCT/KR2018/009425 external-priority patent/WO2019035672A1/ko

2024-06-10 Publication of PL3670529T3 publication Critical patent/PL3670529T3/pl

Links

PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Obesity (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

PL18846196.6T 2017-08-16 2018-08-16 Acylowany analog peptydowy oksyntomoduliny PL3670529T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR20170103798		2017-08-16
PCT/KR2018/009425 WO2019035672A1 (ko)	2017-08-16	2018-08-16	아실화 옥신토모듈린 펩타이드 유사체

Publications (1)

Publication Number	Publication Date
PL3670529T3 true PL3670529T3 (pl)	2024-06-10

Family

ID=65562699

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL18846196.6T PL3670529T3 (pl)	2017-08-16	2018-08-16	Acylowany analog peptydowy oksyntomoduliny

Country Status (20)

Country	Link
US (2)	US11236142B2 (pl)
EP (2)	EP4079757A1 (pl)
JP (2)	JP7211659B2 (pl)
KR (2)	KR102230363B1 (pl)
CN (3)	CN111094331B (pl)
AU (1)	AU2018318672B2 (pl)
BR (1)	BR112020003319A2 (pl)
CA (1)	CA3073011C (pl)
ES (1)	ES2973986T3 (pl)
HR (1)	HRP20240371T1 (pl)
HU (1)	HUE065912T2 (pl)
IL (1)	IL272606B2 (pl)
MX (2)	MX2020001761A (pl)
PH (1)	PH12020500338A1 (pl)
PL (1)	PL3670529T3 (pl)
RS (1)	RS65414B1 (pl)
RU (1)	RU2752787C1 (pl)
SA (2)	SA522432563B1 (pl)
SG (1)	SG11202001283PA (pl)
SM (1)	SMT202400097T1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2021203645B2 (en) *	2020-04-20	2024-06-27	Hanmi Pharm. Co., Ltd.	Composition for prevention or treatment of hyperlipidemia comprising trigonal glucagon/GLP-1/GIP receptor agonist or conjugate thereof and method using the same
KR102154959B1 (ko) *	2020-04-29	2020-09-10	동아에스티 주식회사	지속형 glp-1 및 글루카곤 수용체 이중작용제
CN115975057B (zh) *	2023-03-16	2023-05-16	杭州信海医药科技有限公司	一种可妥度肽的固相合成方法
KR20250047495A (ko)	2023-09-27	2025-04-04	기은서	불포화 지방산이 들어간 샌드위치의 제조방법
WO2025080717A1 (en) *	2023-10-10	2025-04-17	The Trustees Of Columbia University In The City Of New York	Intranasal delivery of tirzepatide to treat obesity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2007221366B2 (en) *	2006-02-22	2012-08-23	Msd Italia S.R.L.	Oxyntomodulin derivatives
JP5635530B2 (ja) *	2008-12-15	2014-12-03	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
ES2439499T3 (es) *	2008-12-15	2014-01-23	Zealand Pharma A/S	Análogos de glucagón
US8680049B2 (en) *	2008-12-15	2014-03-25	Zealand Pharma A/S	Glucagon analogues
WO2010096052A1 (en) *	2009-02-19	2010-08-26	Merck Sharp & Dohme Corp.	Oxyntomodulin analogs
AR081975A1 (es) *	2010-06-23	2012-10-31	Zealand Pharma As	Analogos de glucagon
MA34383B1 (fr) *	2010-06-24	2013-07-03	Zealand Pharma As	Analogues de glucagon
SI2721062T1 (sl) *	2011-06-17	2019-03-29	Hanmi Science Co., Ltd.	Konjugat, obsegajoč oksintomodulinski in imunoglobinski fragment, in uporaba le-tega
PE20142113A1 (es) *	2011-12-23	2014-12-03	Zealand Pharma As	Analogos de glucagon
WO2013157002A1 (en) *	2012-04-19	2013-10-24	Prolor Biotech Inc.	Long-acting oxyntomodulin variants and methods of producing same
CN104684576B (zh) *	2012-06-04	2019-08-06	奥普科生物制品有限公司	聚乙二醇化的oxm变体
KR101968344B1 (ko) *	2012-07-25	2019-04-12	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
CN105324125A (zh) *	2013-03-15	2016-02-10	印第安纳大学研究及科技有限公司	具有长效的前体药物
US9988429B2 (en) *	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
CN104926934B (zh) *	2014-09-23	2016-11-09	蒋先兴	胃泌酸调节素类似物
JP6657230B2 (ja) *	2014-09-24	2020-03-04	インディアナユニヴァーシティリサーチアンドテクノロジーコーポレイション	インクレチン−インスリンコンジュゲート
WO2016090628A1 (zh) *	2014-12-12	2016-06-16	北京韩美药品有限公司	胃泌酸调节肽(oxm)类似物、其合成及应用
US20190000928A1 (en) *	2015-06-17	2019-01-03	The California Institute For Biomedical Research	Modified therapeutic agents and compositions thereof
WO2017160669A1 (en) *	2016-03-18	2017-09-21	Merck Sharp & Dohme Corp.	Insulin-incretin conjugates

2018
- 2018-08-16 US US16/638,970 patent/US11236142B2/en active Active
- 2018-08-16 SG SG11202001283PA patent/SG11202001283PA/en unknown
- 2018-08-16 CA CA3073011A patent/CA3073011C/en active Active
- 2018-08-16 HR HRP20240371TT patent/HRP20240371T1/hr unknown
- 2018-08-16 BR BR112020003319-7A patent/BR112020003319A2/pt unknown
- 2018-08-16 KR KR1020180095717A patent/KR102230363B1/ko active Active
- 2018-08-16 ES ES18846196T patent/ES2973986T3/es active Active
- 2018-08-16 RU RU2020108518A patent/RU2752787C1/ru active
- 2018-08-16 AU AU2018318672A patent/AU2018318672B2/en active Active
- 2018-08-16 CN CN201880053473.4A patent/CN111094331B/zh active Active
- 2018-08-16 CN CN202310958807.5A patent/CN116854804A/zh active Pending
- 2018-08-16 EP EP22170622.9A patent/EP4079757A1/en active Pending
- 2018-08-16 CN CN202410003809.3A patent/CN117603337A/zh active Pending
- 2018-08-16 IL IL272606A patent/IL272606B2/en unknown
- 2018-08-16 EP EP18846196.6A patent/EP3670529B1/en active Active
- 2018-08-16 RS RS20240329A patent/RS65414B1/sr unknown
- 2018-08-16 SM SM20240097T patent/SMT202400097T1/it unknown
- 2018-08-16 PL PL18846196.6T patent/PL3670529T3/pl unknown
- 2018-08-16 JP JP2020508489A patent/JP7211659B2/ja active Active
- 2018-08-16 HU HUE18846196A patent/HUE065912T2/hu unknown
- 2018-08-16 MX MX2020001761A patent/MX2020001761A/es unknown
2020
- 2020-02-13 MX MX2024000276A patent/MX2024000276A/es unknown
- 2020-02-14 PH PH12020500338A patent/PH12020500338A1/en unknown
- 2020-02-16 SA SA522432563A patent/SA522432563B1/ar unknown
- 2020-02-16 SA SA520411366A patent/SA520411366B1/ar unknown
- 2020-03-31 KR KR1020200039264A patent/KR102230368B1/ko active Active
2021
- 2021-08-24 US US17/410,697 patent/US11713344B2/en active Active
- 2021-10-27 JP JP2021175902A patent/JP7443315B2/ja active Active

Also Published As

Publication number	Publication date
US11236142B2 (en)	2022-02-01
SG11202001283PA (en)	2020-03-30
EP3670529A1 (en)	2020-06-24
AU2018318672B2 (en)	2021-04-15
CA3073011C (en)	2023-06-13
MX2024000276A (es)	2024-01-31
KR20190019030A (ko)	2019-02-26
MX2020001761A (es)	2020-07-29
CN117603337A (zh)	2024-02-27
EP3670529C0 (en)	2024-01-24
US11713344B2 (en)	2023-08-01
SMT202400097T1 (it)	2024-05-14
EP3670529B1 (en)	2024-01-24
SA522432563B1 (ar)	2024-03-24
HRP20240371T1 (hr)	2024-06-07
CN116854804A (zh)	2023-10-10
ES2973986T3 (es)	2024-06-25
CN111094331A (zh)	2020-05-01
JP2022023179A (ja)	2022-02-07
IL272606A (en)	2020-03-31
RU2752787C1 (ru)	2021-08-05
AU2018318672A1 (en)	2020-02-27
CA3073011A1 (en)	2019-02-21
US20200354425A1 (en)	2020-11-12
SA520411366B1 (ar)	2022-12-27
JP7211659B2 (ja)	2023-01-24
KR102230368B1 (ko)	2021-03-22
CN111094331B (zh)	2024-03-29
BR112020003319A2 (pt)	2020-08-25
JP2020531442A (ja)	2020-11-05
KR102230363B1 (ko)	2021-03-22
US20220119473A1 (en)	2022-04-21
KR20200037186A (ko)	2020-04-08
IL272606B2 (en)	2024-12-01
EP4079757A1 (en)	2022-10-26
HUE065912T2 (hu)	2024-06-28
EP3670529A4 (en)	2021-11-03
JP7443315B2 (ja)	2024-03-05
RS65414B1 (sr)	2024-05-31
PH12020500338A1 (en)	2020-09-28
IL272606B1 (en)	2024-08-01
NZ761754A (en)	2023-09-29

Publication	Publication Date	Title
IL275298A (en)	2020-07-30	Mitochondria-targeted peptides
IL272606A (en)	2020-03-31	An acyl-modified peptide oxyntomodulin analog
GB201719557D0 (en)	2018-01-10	Polypeptide
SG10202109234YA (en)	2021-10-28	Novel peptide
GB201700557D0 (en)	2017-03-01	Novel peptides
SG11202005653RA (en)	2020-07-29	Novel peptide
EP3653063A4 (en)	2021-03-24	PEPTIDE
SG11201705759SA (en)	2017-08-30	Cytotoxic hexim1 peptides and uses thereof
GB201607534D0 (en)	2016-06-15	Peptides
GB201707139D0 (en)	2017-06-21	Polypeptides
GB201612150D0 (en)	2016-08-24	Modified peptide
GB201604468D0 (en)	2016-04-27	Peptides
GB201717918D0 (en)	2017-12-13	Spray configuration
GB201706472D0 (en)	2017-06-07	Tumour-targeting peptide variants
IL275278A (en)	2020-07-30	Elastomeric peptide
GB201713700D0 (en)	2017-10-11	Peptide conjugates
HK40106360A (zh)	2024-09-06	酰化胃泌酸调节素肽类似物
GB201607535D0 (en)	2016-06-15	Peptides
HK40101394A (zh)	2024-05-17	酰化胃泌酸调节素肽类似物
GB201719520D0 (en)	2018-01-10	Neuroprotectvie peptide
GB201715378D0 (en)	2017-11-08	Peptides
GB201715379D0 (en)	2017-11-08	Peptides
GB201711620D0 (en)	2017-08-30	Peptides
GB201707837D0 (en)	2017-06-28	Peptides
GB201717773D0 (en)	2017-12-13	Peptide Synthesis